<DOC>
	<DOCNO>NCT01771705</DOCNO>
	<brief_summary>The purpose study compare two different way monitor immune system determine manage dose anti-rejection medication .</brief_summary>
	<brief_title>NFAT-Dependent Cytokine Gene Expression Immune Monitoring Kidney Transplant Patients</brief_title>
	<detailed_description>This single center randomize controlled trial investigate efficacy safety adjust calcineurin inhibitor ( CNI ) dose base Nuclear Factor Activating T Cells ( NFAT ) -dependent cytokine gene expression compare standard care adjustment base trough level . Before study-related evaluation perform , patient must give write informed consent . Once consent obtain , patient 's eligibility participate study assess within 2 week 6 month management biopsy . Approximately 40 patient meet inclusion criterion randomize University California , San Francisco ( UCSF ) . Eligible patient include patient maintained triple therapy tacrolimus , mycophenolate mofetil , prednisone prior rejection episodes undergone 6 month management kidney biopsy show evidence acute cellular rejection antibody mediate rejection .</detailed_description>
	<criteria>Eligible patient include patient maintained triple therapy tacrolimus , mycophenolate mofetil , prednisone prior rejection episodes undergone 6 month management kidney biopsy show evidence acute cellular rejection antibody mediate rejection . Any patient maintain triple therapy tacrolimus , mycophenolate mofetil steroid and/or evidence rejection 6 month management biopsy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Transplantation</keyword>
	<keyword>Kidney</keyword>
	<keyword>calcineurin inhibitor</keyword>
	<keyword>NFAT</keyword>
	<keyword>tacrolimus</keyword>
</DOC>